肾移植受者使用氢氯噻嗪与角质形成细胞癌风险的相关性
本研究基于法国南特DIVAT数据库2000至2017年单中心队列,纳入肾、胰肾联合及胰腺移植受者共2496例,评估氢氯噻嗪暴露与角质形成细胞癌的关系。多变量病因特异性时变Cox模型显示,氢氯噻嗪暴露与鳞状细胞癌风险升高相关(HR 2.04,95%CI 1.27-3.28),与基底细胞癌无显著关联(HR 0.63,95%CI 0.35-1.15)。
要点
- 肾移植受者氢氯噻嗪暴露与鳞状细胞癌风险约增两倍相关。
- 氢氯噻嗪暴露与基底细胞癌风险无显著关联。
- 移植受者使用氢氯噻嗪需关注鳞状细胞癌筛查。
核心结论
- 在肾、胰肾联合及胰腺移植受者单中心队列中,氢氯噻嗪暴露与鳞状细胞癌风险升高约两倍相关,与基底细胞癌风险无升高相关。
研究设计与样本
- 单中心队列研究,来自法国南特DIVAT数据库,纳入2000至2017年移植的肾(n=2155)、胰肾联合(n=282)及胰腺(n=59)移植受者。
- 采用多变量病因特异性时变Cox模型,以氢氯噻嗪为时变暴露变量,评估其与鳞状细胞癌和基底细胞癌风险的关系。
主要发现
- 2496例受者中279例(11%)移植后暴露于氢氯噻嗪。
- 鳞状细胞癌10年和15年累积发生率分别为7%和9%,基底细胞癌分别为8%和11%。
- 氢氯噻嗪暴露与鳞状细胞癌风险相关(HR 2.04,95%CI 1.27-3.28)。
- 氢氯噻嗪暴露与基底细胞癌无显著关联(HR 0.63,95%CI 0.35-1.15)。
临床怎么用
- 肾移植受者使用氢氯噻嗪时应警惕鳞状细胞癌风险,加强皮肤监测与筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Keratinocyte cancers, which primarily comprise squamous cell carcinomas and basal cell carcinomas, represent a major concern and potential risk for kidney transplant recipients. Hydrochlorothiazide, a diuretic widely used to treat hypertension, has been implicated in skin photosensitivity reaction. Recent studies conducted in the general population have found that hydrochlorothiazide use is associated with a higher risk of keratinocyte cancer, especially squamous cell carcinomas. High-risk groups, however, including transplant recipients were excluded from these. Our aim was to investigate whether hydrochlorothiazide use was associated with keratinocyte cancer in kidney transplant recipients on immunosuppressive therapy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a single-center cohort of kidney (n=2155), combined kidney-pancreas (n=282), and pancreas (n=59) transplant recipients from the Données Informatisées VAlidées Transplantation (DIVAT) database transplanted between 2000 and 2017 in Nantes, France, we evaluated the association between hydrochlorothiazide exposure and keratinocyte cancers. Multivariable cause-specific, time-varying Cox models were used to estimate the relationship between hydrochlorothiazide exposure and the hazard of squamous cell carcinoma and basal cell carcinoma, with hydrochlorothiazide designated as the time-dependent variable. RESULTS: Among the participants, 279 of 2496 (11%) were exposed to hydrochlorothiazide after the transplantation. Cumulative incidence rates of keratinocyte cancer by 10 and 15 years were 7% and 9% for squamous cell carcinomas, respectively, and 8% and 11% for basal cell carcinomas, respectively. We found a relationship between exposure to hydrochlorothiazide and the risk of squamous cell carcinomas (hazard ratio, 2.04; 95% confidence interval, 1.27 to 3.28). In contrast, we found no association between hydrochlorothiazide exposure and basal cell carcinomas (hazard ratio, 0.63; 95% confidence interval, 0.35 to 1.15). CONCLUSIONS: In a single-center cohort of kidney, combined kidney-pancreas, and pancreas transplant recipients, exposure to hydrochlorothiazide was associated with a two-fold higher risk of squamous cell carcinoma and no higher risk of basal cell carcinoma.
引用
- Letellier T, Leborgne F, Kerleau C, et al. Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2020. PMID: 33172936. doi:10.2215/CJN.02560220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。